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CObjective: To estimate the cost of illness (COI) andhealth-related qual-
ity of life (HRQOL) of rheumatoid arthritis (RA) according to four differ-
ent levels of functional severity. Methods: A face-to-face interview
survey was administered to patients with RA recruited at the Rheuma-
tology Clinic of Seoul National University Hospital. Direct costs (medi-
cal costs [treatment, drug, private physiotherapy, traditional Chinese
medicine, other alternative medicine], nonmedical costs [travel, di-
etary supplements, auxiliary device, home assistance]), indirect costs
(productivity loss due to job loss and sick leave), and deterioration in
the HRQOL of patients with RAweremeasured. Factors associatedwith
the COI and theHRQOLwere analyzed by usingmultiple regression and
multivariate logistic regression. Results: A total of 196 patients were
enrolled for this study. As RA functional severity worsened, the total
costs increased accordingly (class I: 4,230,204 Korean won, class II: O
v
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t
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t
e no
-gu,
, Sou
al So
oi:10.1016/j.jval.2011.11.020,250,674 Korean won, class III: 8,046,434 Korean won, class IV:
,206,215 Korean won). Direct costs also increased with the severity of
he functional status, with a sharp decrease in class IV. The average
RQOL score was 0.49, showing an evident impact of RA severity (class
: 0.67, class II: 0.50, class III: 0.29, class IV: 0.23). Functional class and
omorbidity were significant determinants of the COI and the HRQOL.
onclusion: Functional severity was a major factor associated with
igher COI and lower HRQOL scores. Therefore, preventing the aggra-
ation of functional severity is crucial for decreasing the COI and im-
roving the HRQOL of patients with RA.
eywords: cost, functional status, quality of life, rheumatoid arthritis.
opyright © 2012, International Society for Pharmacoeconomics and
utcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Rheumatoid arthritis (RA) is a chronic autoimmune disease that is
primarily manifested by pain and swelling of multiple synovial
joints. The exact cause of RA is unknown, but it is thought to be
multifactorial, with genetic predisposition and environmental fac-
tors (infection, smoking, or hormones) believed to play a role [1,2].
ymptoms of RA vary depending on the degree of inflammation
nd include joint pain and stiffness, fatigue, anorexia, and low-
rade fever. Inflammatory reactions in the joints occur commonly
n a symmetric manner. RA can also manifest as a systemic auto-
mmune disease that affects the musculoskeletal, nervous, respi-
atory, cardiovascular, renal, and hematological systems.
The worldwide prevalence of RA is estimated to be around 1%,
ffectingwomen two or three timesmore thanmen. In South Korea,
he self-reported prevalence rate of RA based on the National Health
ndNutrition ExaminationSurveywas estimated to be 2.1% [3]while
he physician-diagnosed prevalence rate of RA based on community
urveys was estimated to be 1.4% [4]. If left untreated, 20% to 30% of
atients with RA suffer from permanent joint damage within 2 to 3
ears of diagnosis; theymay also have difficulty in carrying out nor-
al daily activities. Moreover, complications from RA can arise dur-
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ublished by Elsevier Inc.ing the disease course. For these reasons, RA requires an early treat-
ment once it is diagnosed [5].
Because RA is a chronic disease accompanied by physical dis-
abilities and a number of comorbidities, it results in a significant
economic burden, reduced productivity, and deteriorated quality
of life (QOL) [6]. McIntosh [7] reported that the total cost of RA in
England was estimated to be more than £1.2 billion, of which 52%
was indirect costs. Leardini et al. [8] noted that the disease burden
aried depending on the functional status of the patients with RA,
ith directmedical costs increasing and theQOLdecreasing as the
unctional status worsened. A comparative analysis of 1415 pa-
ientswith RA and a control group conducted by Birnbaumet al. [9]
rom 1995 to 1997 indicated that the total medical and drug cost
nd productivity loss incurred by these patients amounted to
7193 per person per year, 2.11 times higher than that of the con-
rol group, which totaled $3405. Rat and Boissier [10] and Pugner et
al. [11] conducted studies of the RA burden and concluded that, on
average, indirect costs accounted for 64% (20%–79%) of the total RA
burden. This indicates that the cost of productivity loss due to the
physical disabilities caused by RA is considerable worldwide.
Published evidence of the burden of RA in South Korea is very
limited. The only reported cost-of-illness (COI) study was on the
conflicts of interest with regard to the content of this article.
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this study, the mean direct cost was found to be Korean won
(KRW) 181K per patient per month while the mean indirect cost
ranged fromKRW83K toKRW106Kper patient permonth depend-
ing on the location of residence [12]. In a study that estimated the
QOL of 100 patients with RA and 228 healthy people by using the
Korean version of European quality of life-five dimensions (KEQ-
5D) tool, the QOL of patients with RA was 0.58 whereas that of
healthy people was 0.91, indicating that patients with RA had a far
lower QOL than did healthy controls [13].
The results of burden-of-disease studies can be used for prior-
itizing health policies and justifying the needs for spending on
disease prevention,management, and social intervention. As very
few such studies have been performed in South Korea, the present
study was performed to assess the COI and impact of RA on the
health-related quality of life (HRQOL). Particularly, we investi-
gated the differences in the COI and the HRQOL according to the
functional status of patients with RA to improve the understand-
ing of the true burden of RA.
Methods
The following data sources were used to estimate the COI and the
HRQOL of patients with RA: patient surveys, medical chart re-
views, and reviews of electronic hospital records.
Patients
Patients with RA were enrolled at the Rheumatology Clinic of
Seoul National University Hospital, which is located in Seoul,
South Korea, between November 18, 2009, and February 2, 2010.
The inclusion criteria were as follows: 1) the patient meets the
American Rheumatism Association 1987 revised criteria for
the classification of RA [14] and 2) the patientmust have visited the
medical institution at least twice before the interview. Functional
status was assessed according to the American College of Rheu-
matology 1991 revised criteria for the classification of global func-
tional status in RA [15]. Definitions of the four classes were as fol-
lows: 1) class I: completely able toperformtheusual activities of daily
living (self-care, vocational, and avocational), 2) class II: able to per-
form the usual self-care activities and vocational activities but lim-
Table 1 – Sociodemographic characteristics of the patients
Class I
The number of patients 66 (33.7)
Gender (female) 53 (80.3)
Age (y), mean (SD) 60.2 (11.2)
Marital status
Married 57 (86.4)
Widowed 5 (7.6)
Others 4 (6.1)
Household monthly income, mean (SD) 3806 (5300)
Unemployment 42 (63.6)
Education
Elementary school or less 9 (13.6)
Middle school 7 (10.6)
High school 30 (45.5)
College 20 (30.3)
Health insurance
National health insurance 64 (97.0)
Medical aid 2 (3.0)Household monthly income: X1000 Korean won.ited in the ability to perform avocational activities, 3) class III: able to
perform the usual self-care activities but limited in the ability to per-
form vocational and avocational activities, and 4) class IV: limited in
the ability to perform theusual self-care, vocational, and avocational
activities. Usual self-care activities include dressing, bathing, groom-
ing, and toileting. Avocational (recreation and/or leisure) and voca-
tional (work, school, homemaking) activities are patient desired and
specific to age and sex. This study was carried out with the approval
of the Institutional Review Board of the hospital.
Data
Sociodemographic and clinical characteristics
Information on sociodemographic characteristics such as age, gen-
der, marital status, household income, employment status, educa-
tional status, and health insurance type were collected by using the
data from the patient surveys. Information on clinical features was
collected from reviews of medical charts, which included informa-
tion pertaining to comorbidity, the duration of morning stiffness,
rheumatoid factor, bone erosion, andmedication.
Cost of illness
In the view of South Korean circumstances, direct medical costs in-
cluded in-hospital, prescription drugs, private physiotherapy, tradi-
tional Chinese medicine, and other alternative medicine costs,
whereas direct nonmedical costs included travel, auxiliary devices,
dietary supplements, and home assistance costs. Indirect costs in-
cluded productivity loss from job loss and sick leave [16,17]. Produc-
tivity loss related to career changes, in other words reduced produc-
tivity at work, was not considered in the analysis of indirect costs,
because there was one patient who reported a RA-related career
change andwhose average wage did not change. Because it was im-
possible to estimate the mortality rate of patients with RA, lost pro-
ductivity from premature death is not reflected in this study.
In-hospital costs were estimated from hospital electronic data
records based on the expense for the physician visit, treatments,
hospitalization, and monitoring throughout the year of 2009. Out-
of-hospital medical costs, direct nonmedical costs, and indirect
costs were estimated on the basis of patient surveys from face-to-
face interviews. The reference period for out-of-hospital medical
rheumatoid arthritis.
n (%)
ss II Class II Class IV Total
(41.3) 32 (16.3) 17 (8.7) 196 (100)
(80.2) 28 (87.5) 13 (76.5) 159 (81.1)
(10.1) 64.3 (12.1) 66.9 (9.6) 62.5 (10.8)
(86.4) 21 (65.6) 13 (76.5) 161 (82.1)
(12.3) 9 (28.1) 2 (11.8) 26 (13.3)
(1.2) 2 (6.3) 2 (11.8) 9 (4.6)
(3186) 1540 (1579) 2187 (2466) 2836 (3872)
(81.5) 29 (90.6) 14 (82.4) 151 (77.4)
(32.1) 13 (40.6) 7 (41.2) 55 (28.2)
(18.5) 3 (9.4) 3 (17.6) 28 (14.4)
(27.2) 11 (34.4) 6 (35.3) 69 (35.4)
(21.0) 5 (15.6) 1 (5.9) 43 (22.1)
(98.8) 27 (84.4) 14 (82.4) 185 (94.4)
(1.2) 5 (15.6) 3 (17.6) 11 (5.6)with
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Productivity loss caused by the disease-related job loss was esti-
mated by applying the duration of the patient’s unemployment
until the normal retirement age and annual increase in wages to
the wage the patient received before the loss of work. It was as-
sumed that the age at retirement was 60 years for both genders.
The annual wage increase rate was obtained from the Korean Sta-
tistical Information Service [18].
Health-related quality of life
The HRQOL of the patients was analyzed on the basis of face-to-face
interview questionnaires using the KEQ-5D. Utility values were ob-
Table 2 – Clinical characteristics of the patients with rheum
Class I
The number of patients 66 (33.7)
Disease duration (y), mean (SD) 11.4 (7.5)
Comorbidity 33 (50.0)
Hypertension 14 (21.2)
Osteoporosis 6 (9.1)
Diabetes mellitus 5 (7.6)
Morning stiffness 30 (45.5)
Morning stiffness duration (h), mean (SD) 0.3 (0.7)
Rheumatoid factor 49 (74.2)
Bone erosion 25 (37.9)
Drugs
Methotrexate 52 (50.1)
Hydroxychloroquine 26 (29.6)
Leflunomide 8 (9.1)
Sulfasalazine 7 (8.0)
Biologic agents 3 (3.4)
Table 3 – Direct and indirect cost per patient per year accor
Class I Class II
Cost
(KRW 1000)
% Cost
(KRW 1000)
Mean SD Mean SD
Direct cost
Medical cost
In-hospital cost 548 1,264 13 690 1,612
Prescription drugs 787 874 18.6 1,033 1,144
Private physiotherapy 45 294 1.1 70 288
Chinese medicine 39 237 0.9 102 612
Other alternative medicine 86 442 2 52 301
Subtotal 1,505 1,722 35.6 1,948 2,092
Nonmedical cost
Travel expense 65 139 1.5 117 350
Auxiliary devices 14 46 0.3 21 84
Dietary supplements 509 883 12 463 973
Home assistance‘ 380 1,592 9 378 1,616
Subtotal 968 1,798 22.9 978 2,061
Total direct cost 2,473 2,847 58.5 2,926 2,816
Indirect cost
Sick leaves 12 65 0.3 11 57
Loss of work 1,745 8,020 41.3 4,314 21,204
Total indirect cost 1,757 8,018 41.5 4,325 21,202
Total cost 4,230 8,427 100 7,251 21,170ACR, American College of Rheumatology; KRW, Korean won.tained through a tariff system developed in South Korea, which ap-
plied a time trade-off method to derive preferences on different
health statuses from 287 adults residing in urban areas [19].
Data analysis
Descriptive statistics (frequency, percentage, mean, and SD) were
used to analyze the patient characteristics, costs, and the HRQOL.
To identify the factors affecting the total costs, direct costs, and
the HRQOL, multiple regression analysis was used, and to identify
the factors affecting the incidence of indirect costs, multivariate
logistic regression was used.
id arthritis.
n (%)
lass II Class II Class IV Total
81 (41.3) 32 (16.3) 17 (8.7) 196 (100)
.3 (8.3) 18.9 (9.9) 17.7 (12.2) 14.3 (9.2)
46 (56.8) 21 (65.6) 16 (94.1) 116 (59.2)
24 (29.6) 8 (25.0) 6 (35.3) 52 (26.5)
13 (16.0) 9 (28.1) 6 (65.3) 34 (17.3)
6 (7.4) 1 (3.1) 3 (17.6) 15 (7.7)
52 (64.2) 22 (68.8) 10 (58.8) 114 (58.2)
.5 (4.0) 2.8 (5.8) 2.4 (5.8) 1.4 (4.0)
50 (61.7) 16 (50.0) 10 (58.8) 125 (65.8)
37 (45.7) 18 (56.3) 7 (41.2) 87 (46.0)
71 (87.7) 23 (71.9) 14 (82.4) 160 (81.6)
44 (54.3) 11 (34.4) 7 (41.2) 88 (44.9)
16 (19.8) 6 (18.8) 2 (11.8) 32 (16.3)
11 (13.6) 7 (21.9) 3 (17.7) 28 (14.3)
4 (4.9) 2 (6.3) 0 (0.0) 9 (4.6)
to the ACR functional classes.
Class III Class IV Total
Cost
(KRW 1000)
% Cost
(KRW 1000)
% Cost
(KRW 1000)
%
Mean SD Mean SD Mean SD
5 850 1,994 10.6 774 851 9.5 676 1,528 10.5
2 2,520 4,092 31.3 1,377 1,451 16.8 1,223 2,008 19
29 132 0.4 12 46 0.1 50 259 0.8
4 28 83 0.3 5 21 0.1 60 420 0.9
7 145 568 1.8 71 282 0.9 80 405 1.3
9 3,572 4,262 44.4 2,238 1,613 27.3 2,089 2,546 32.4
6 142 205 1.8 241 697 2.9 114 329 1.8
3 44 105 0.5 93 237 1.1 29 104 0.4
4 514 1,182 6.4 163 298 2 461 948 7.2
2 813 1,911 10.1 — — — 417 1,607 6.5
5 1,513 2,362 18.8 497 979 6.1 1,020 1,976 15.8
4 5,084 4,804 63.2 2,736 1,641 33.3 3,109 3,287 48.2
2 37 192 0.5 — — — 14 94 0.2
5 2,925 6,577 36.4 5,471 13,660 66.7 3,323 15,178 51.5
6 2,962 6,564 36.8 5,471 13,660 66.7 3,337 15,241 51.8
8,046 8,201 100 8,206 13,665 100 6,446 15,457 100ato
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Patient demographics
In total, 196 patients were consecutively enrolled in this study.
Themajority of themwere women, 159 patients (81.1%), and the
mean age (SD) was 62.5 (10.8) years. RA functional status clas-
sified by the American College of Rheumatology showed that 66
patients (33.7%) were in class I, 81 patients (41.3%) in class II, 32
patients (16.3%) in class III, and 17 patients (8.7%) in class IV. Of
note, the mean age (SD) of patients in class IV was 66.9 (9.6)
years whereas the mean age (SD) of patients in class I was 60.2
(11.2) years. Overall, 77.4% of the patients with RA were unem-
ployed (Table 1).
Clinical characteristics
The mean disease duration (SD) of all of the patients with RA was
14.3 (9.2) years. It was shortest in patients in class I and longest in
those in class IV, at 11.4 and 17.7 years, respectively. This high-
lights that RA is a chronic disease and becomes more severe over
time. More than half of the patients reported comorbidities, and
the rate increasedwith the deterioration in functional status, from
50.0% in class I to 94.1% in class IV. Themost frequent comorbidity
was hypertension followed by osteoporosis and diabetes mellitus.
With respect to disease-modifying antirheumatic drugs, metho-
trexate was the most frequently prescribed drug (81.6%), followed
by hydroxychloroquine (44.9%), leflunomide (16.3%), and sul-
fasalazine (14.3%); Nine (4.6%) patients were treated with biologic
agents (Table 2).
Cost of illness
The average total COI was estimated to be KRW 6.45 million (US
$1  KRW1090 as of May 18, 2011) per person per year. Of the
total, direct costs amounted to KRW 3.11million (48.2%), slightly
lower than indirect costs, which amounted to KRW 3.34 million
(51.8%) (Table 3).
The total cost of RA increased with the degree of functional
severity, from KRW 4.23 million per patient per year in class I to
KRW 8.21 million in class IV. Direct medical costs revealed the
same trend for classes I through III but then decreased in class IV.
Outpatient prescription drugs accounted for the largest share of
direct medical costs (class I: 18.6%, class II: 14.2%, class III: 31.3%,
class IV: 16.8%). Direct nonmedical costs also increased with the
worsening of the functional status in the first three classes but
decreased in class IV.
The indirect costs also increased with the deterioration of the
functional status. The total amount of productivity loss rose as the
functional severity deteriorated, from KRW 1.76 million in class I
to KRW 5.47 million in class IV. Loss of work as an indirect cost
accounted for most of the total productivity loss. Around 77% of
the patients were unemployed at the time of the survey, and 25%
of the unemployed patients reported that they were forced to quit
their job because of their illness, showing that a considerable pro-
ductivity loss associated with loss of work has arisen in patients
with RA. The sick leave costs were also substantially higher in
patients in class III than they were for those in classes I and II,
though this cost was not present in class IV. As the patients in
class IV had a greater degree of physical disability, they had diffi-
culty maintaining employment.
Health-related quality of life
The overall HRQOL of the patients with RA was estimated to be
0.49. Regarding functional severity, the HRQOL values of classes I,
II, III, and IV were estimated to be 0.67, 0.50, 0.29, and 0.23, respec-
tively. This indicates that the HRQOL of the patients with RA de-T M S U P A K A
S47V A L U E I N H E A L T H 1 5 ( 2 0 1 2 ) S 4 3 – S 4 9teriorated as their functional severity worsened (Table 4). Given
that 0 indicates death and 1 indicates perfect health (KEQ-5D an-
chors), the progression of RA resulted in a substantial deteriora-
tion in the HRQOL.
In all dimensions covered by the KEQ-5D, including mobility,
self-care, usual activity, pain/discomfort, and anxiety/depression,
the percentage of patientswith problems increased as theymoved
from class I to class IV. Of particular note, the percentage of pa-
tients with severe problems was considerably higher in class IV
than in the other classes.
Factors affecting the COI and the HRQOL
The results of the multiple regression and multivariate logistic
regression showed that the functional severity and comorbidity
were significant determinants of both total and direct costs. Major
factors affecting indirect costs were age, educational status,
household income, and comorbidity.
In terms of functional severity, classes I and II showed lower
total and direct costs than did classes III and IV. In terms of
educational status, one of the major factors affecting indirect
costs, those with a high school education had a lower probabil-
ity of incurring indirect costs than were those with a college
degree. Household income, comorbidity, and age also affected
the occurrence of indirect costs at the 10% significance level
(Table 5).
The HRQOL was affected by residential area, functional sta-
tus, and comorbidity. As for functional status, the patients in
classes I and II showed higher HRQOL scores than did those in
classes III and IV. Patients with comorbidity had lower HRQOL
Table 5 – Multiple regressions and multivariate logistic reg
Variables Total cost (log)
Regression
coefficient
SE P
Gender
Female 0.079 0.197 0.690
Age
Age 0.019 0.028 0.501
Age squared 0.039 0.265 0.884
Region
Seoul 0.209 0.211 0.322
Gyeonggi 0.254 0.231 0.275
Other — — —
Marital status
Married 0.271 0.209 0.196
Education
Elementary school or less 0.435 0.256 0.091
Middle school 0.220 0.271 0.419
High school 0.348 0.217 0.111
College — — —
Household income 0.000 0.000 0.261
Comorbidity 0.318 0.079 0.000
Functional status
Class I 0.821 0.208 0.000
Class II 0.465 0.194 0.018
Class III, IV — — —
Intercept 17.002 0.602 0.000
F  3.740, P  0.000 Adj. R2  0.153
OR, odds ratio; SE, standard error.
* Indirect cost occurred: 1, not occurred: 0.scores than did those without (Table 6).Discussion
According to this study, the average COI of patients with RA was
estimated to be KRW 6.45 million per person in 2009. In detail,
indirect costs accounted for 51.8% of the total cost, slightly higher
than direct costs. In studies from other countries, indirect costs
made up 35% to 37% of the total cost in the United States and
Canada and 54.4% inWestern Europe [20]. Given that the majority
of patients with RA are female, the indirect cost of patients with
RA may be related to the level of productivity of women in the
labor market of each country. It is considered that the level of
productivity of Korean women is likely not higher than that of
women inWestern European countries. In the United States, how-
ever, the lower percentage of indirect costs is linked to a relatively
high percentage of expenditure on prescription drugs. The abso-
lute amount of the indirect cost in the United States is not lower
than that in European countries. Therefore, special attentionmust
be paid in any attempt to conduct cross-country comparisons.
This study showed that the COI increased with the deteriora-
tion of functional status. This was consistent with the results of
earlier research conducted by Leardini et al. [8] in Italy. Therewere
differences, however, in the compositions of the total costs. In the
study by Leardini et al. [8], indirect costs accounted for 55% in class
I and remained at 70% or higher thereafter. In our study, on the
other hand, indirect costs amounted to 41.5% in class I, 59.7% in
class II, 36.8% in class III, and 66.7% in class IV, showing a smaller
percentage in class III. Further analysis revealed that this differ-
ence resulted from the lower wage that the class III patients used
to receive before leaving their jobs because of RA compared with
this metric in the other classes.
This study also showed that direct costs rose continuously
ion model for cost of illness.
Direct cost (log) Indirect cost*
Regression
coefficient
SE P OR SE P
0.146 0.148 0.328 0.570 0.316 0.311
0.001 0.021 0.980 0.999 0.080 0.986
0.004 0.200 0.982 0.272 0.209 0.089
0.116 0.159 0.467 0.615 0.355 0.399
0.094 0.174 0.592 0.862 0.545 0.815
— — — — — —
0.129 0.157 0.412 1.611 1.074 0.475
0.108 0.193 0.575 0.649 0.480 0.559
0.012 0.205 0.954 0.715 0.542 0.658
0.186 0.164 0.258 0.270 0.178 0.047
— — — — — —
0.000 0.000 0.763 0.998 0.001 0.066
0.239 0.060 0.000 1.575 0.386 0.064
0.594 0.157 0.000 0.380 0.238 0.123
0.364 0.146 0.014 0.661 0.353 0.439
— — — — — —
14.452 0.454 0.000
F  3.500, P  0.000 Adj. R2  0.141 2(13)  43.770, P  0.000ressfrom class I to class III but then sharply decreased in class IV. This
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goals over time in a direction from symptomatic improvement
toward prevention andmanagement as RA becomes worse. In the
study conducted by Leardini et al. [8], however, direct medical
costs were the highest in class IV. This difference can be explained
by the different durations of the disease: a mean of 17.7 years in
our study compared with amean of 2.6 years in the study by Lear-
dini et al. In South Korea, it is understood that early diagnosis and
treatment of RA does not prevail, and few patients visit a physi-
cian in the early stage of the disease. Delayed referral of these
patients to RA specialists further explains the high rate of ad-
vanced disease among the patients. According to a survey of South
Korean patients with RA, bone erosion was observed in 40% of the
patients at the time of their visit to RA specialists [21].
The QOL was estimated using the KEQ-5D and the tariffs sug-
ested by Kang et al. [19], with the results of utility values as fol-
ows: class I 0.67, class II 0.5, class III 0.29, and class IV 0.23. This
ndicates a decreased HRQOL with lower functional status, which
s consistent with the results of other studies [8]. The average
RQOL of the patients in this studywas 0.49, lower than the scores
f 0.58, 0.58, and 0.57, respectively, estimated in studies conducted
y Kim et al. [13], Yun et al. [22], and Seong et al. [23]. These differ-
ences are thought to be attributed to the different tariffs used in
each study. The present study used a tariff specifically designed
for South Korean people, whereas the previous studies used the
tariffs that were developed in other countries. South Koreans tend
to evaluate their HRQOL to be rather lowwhen they have problems
in at least one out of the five dimensions [19], which may account
for the lower HRQOL score measured in this study compared with
those in the previous studies [13,22,23].
Our analysis found that the major factors affecting the total
Table 6 – Multiple regression model for quality of life.
Variables KEQ-5D utility
Regression
coefficient
SE P
Gender
Female 0.037 0.044 0.402
Age
Age 0.005 0.006 0.386
Age squared 0.042 0.059 0.484
Region
Seoul 0.105 0.047 0.028
Gyeonggi 0.126 0.052 0.015
Other — — —
Marital status
Married 0.004 0.047 0.933
Education
Elementary school or less 0.053 0.057 0.356
Middle school 0.099 0.061 0.105
High school 0.024 0.049 0.627
College — — —
Household income 0.000 0.000 0.880
Comorbidity 0.037 0.018 0.040
Functional status
Class I 0.357 0.046 0.000
Class II 0.227 0.043 0.000
Class III, IV — — —
Intercept 0.372 0.135 0.006
F  8.850, P  0.000
Adj. R2  0.340
KEQ-5D, Korean version of European quality of life-5 dimensions;
SE, standard error.costs and direct costs were the functional class and comorbidity,whereas socio-demographic variables such as age, educational
status, and household income mainly affected the occurrence of
indirect costs. There are not many studies covering analyses of
factors affecting the COI. Leardini et al. [8] showed a statistically
significant difference in the COI in four groupswith different func-
tional statuses, whereas Jaarsveld et al. [24] used logistic regres-
sion analysis targeting only two groups with the lowest and high-
est direct costs to indicate that the degree of functional severity
and age significantly affected theCOI. Thus, itwill be reasonable to
conclude that the most significant factor affecting the COI of pa-
tients with RA is deterioration of the functional status.
The analysis of factors associated with the HRQOL drew a re-
sult similar to that associated with the COI in that functional sta-
tus and comorbidity were the twomost significant factors. In their
study of the HRQOL of patients with RA in South Korea, Kim et al.
[13] showed that functional status was significantly related to
HRQOL as well as a variety of clinical features. In addition, Kojima
et al. [25] and Alishiri et al. [26] confirmed that functional status
significantly influenced HRQOL scores.
This study was carried out with 196 patients at a single hospi-
tal, and the number of patients was not evenly distributed
throughout the four classes. Therefore, there is a limitation in
generalizing the result derived from this study. In addition, it will
be difficult to eliminate all potential sources of recall bias, because
a retrospective approach was applied for the estimation of non-
medical costs such as dietary supplements and auxiliary devices.
Conclusion
This study investigated functional-status–based COI and HRQOL
in 196 patients with RA who were being treated at a tertiary refer-
ral university hospital in Seoul, South Korea. The average COI per
person increased as the functional status deteriorated, whereas
the HRQOL score decreased with the deterioration of the func-
tional status. Therefore, prevention of the aggravation of func-
tional severity is crucial for reducing the COI and improving the
HRQOL scores of patients with RA. This is the first study in South
Korea that estimated the COI of RA from a societal perspective.
This study is expected to serve as useful material to improve our
understanding of the burdens of patients with RA in Korea and as
a good reference for those developing related health policies in the
future. Further population-based, prospective research is neces-
sary for a detailed analysis of changes in the COI according to
changes in the functional status of patients with RA.
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